BeyondSpring CEO Dr. Lan Huang Named to PharmaVOICE 100 Most Inspiring People in Life Sciences
August 10, 2021 08:00 ET
|
BeyondSpring, Inc.
Distinguished industry executive and entrepreneur recognized for the development of a first-in-class asset in the oncology space NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the...
BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type
August 04, 2021 07:00 ET
|
BeyondSpring, Inc.
Study met primary endpoint showing statistically significant improvement in overall survival (OS) for the combination vs. docetaxel.Study met key secondary endpoints showing statistically significant...
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
July 14, 2021 07:30 ET
|
BeyondSpring, Inc.
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today...
BeyondSpring to Participate in the William Blair Biotech Focus Conference
July 08, 2021 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications
June 17, 2021 16:00 ET
|
BeyondSpring, Inc.
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
June 16, 2021 08:00 ET
|
BeyondSpring, Inc.
- NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for plinabulin plus G-CSF for the prevention of CIN. A PDUFA date of November 30, 2021 has been assigned by the FDA -...
BeyondSpring to Host First Quarter Financial Results and Corporate Update Conference Call on June 16, 2021
June 11, 2021 08:00 ET
|
BeyondSpring, Inc.
NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today...
BeyondSpring Announces Final Positive Data from the PROTECTIVE-1 Phase 3 CIN Program of Plinabulin as a Single Agent Compared to Pegfilgrastim at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 10, 2021 07:00 ET
|
BeyondSpring, Inc.
- Data further supports plinabulin’s fast onset of action and CIN prevention benefit in week 1 following chemotherapy - Single agent plinabulin (day 1 dose as chemotherapy), had...
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting
June 08, 2021 07:00 ET
|
BeyondSpring, Inc.
NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer...
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 07, 2021 07:00 ET
|
BeyondSpring, Inc.
- Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better...